

Product datasheet for TL314802V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Apc10 (ANAPC10) Human shRNA Lentiviral Particle (Locus ID 10393)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Apc10 (ANAPC10) Human shRNA Lentiviral Particle (Locus ID 10393)

Locus ID: 10393

Synonyms: APC10; DOC1

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: ANAPC10 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001256706, NM 001256707, NM 001256708, NM 001256709, NM 001256710,

NM 001256711, NM 001256712, NM 001318367, NM 014885, NR 046345, NM 014885.1, NM 014885.2, NM 014885.4, NM 001256710.1, NM 001256706.1, NM 001256707.1, NM 001256708.1, NM 001256709.1, NM 001256712.1, NM 001256711.1, BC005217,

BC005217.1, NM 001256706.2

UniProt ID: Q9UM13

Summary: ANAPC10 is a core subunit of the anaphase-promoting complex (APC), or cyclosome, a

ubiquitin protein ligase that is essential for progression through the cell cycle. APC initiates sister chromatid separation by ubiquitinating the anaphase inhibitor securin (PTTG1; MIM 604147) and triggers exit from mitosis by ubiquitinating cyclin B (CCNB1; MIM 123836), the activating subunit of cyclin-dependent kinase-1 (CDK1; MIM 116940) (summary by Wendt et

al., 2001 [PubMed 11524682]).[supplied by OMIM, Feb 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).